Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, discuss the current treatment landscape in colorectal cancer liver metastases, highlighting unmet needs in the treatment space.
Reported revenues of $5.7 million in 4Q23, up 77% over prior year
Full year revenues of $18.5 million, up 49% over prior year
Gross Margin of 90% in 4Q23 and 86% for full year
CMS.
Provider and patient perspectives on why patient education about FGFRi treatment-associated adverse events and how to manage them are is essential in helping patients maintain a good quality of life and stay on treatment.